Tibet AIM Pharm. Inc. (SHE:002826)
19.50
-0.02 (-0.10%)
Apr 30, 2026, 3:04 PM CST
Tibet AIM Pharm. Revenue
Tibet AIM Pharm. had revenue of 182.58M CNY in the quarter ending March 31, 2026, with 22.92% growth. This brings the company's revenue in the last twelve months to 670.32M, up 4.74% year-over-year. In the year 2025, Tibet AIM Pharm. had annual revenue of 636.27M, down -2.39%.
Revenue (ttm)
670.32M
Revenue Growth
+4.74%
P/S Ratio
5.45
Revenue / Employee
1.66M
Employees
403
Market Cap
3.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 636.27M | -15.61M | -2.39% |
| Dec 31, 2024 | 651.88M | -15.16M | -2.27% |
| Dec 31, 2023 | 667.04M | -189.70M | -22.14% |
| Jan 1, 2023 | 856.73M | 131.28M | 18.10% |
| Jan 1, 2022 | 725.46M | 122.84M | 20.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.76B |
| PKU HealthCare Corp.,Ltd. | 1.48B |
| Nanjing Well Pharmaceutical Group | 1.34B |
| Huaren Pharmaceutical | 1.33B |
| Zhejiang Cheng Yi Pharmaceutical | 790.86M |
| Harbin Medisan Pharmaceutical | 789.42M |
| Qianjiang Yongan Pharmaceutical | 783.17M |
| Tuoxin Pharmaceutical Group | 378.34M |